• Orexo outlined its shift toward partner-funded development at its Q3 2026 earnings call, attended by CEO Nikolaj Sorensen and CFO Fredrik Jarrsten.
• Management targets cash runway beyond 2027 without partnership income, supported by a rights issue; quarter-end own cash totaled SEK 62 million.
• Izipry’s FDA resubmission on September 29 carries an expected six-month review, targeting US approval by the end of Q1 2027.
• OX640’s first pivotal trial is scheduled to begin in Q4, with results expected in the first half of 2027; partnering discussions continue.
• A proposed Justice Department settlement would require payments of up to $4 million over several years; principal terms are agreed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orexo AB published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.